NCT06114108: salVage

Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients

Recruiting now NA Last updated 2 April 2026

What this trial tests

NA trial testing Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy) in Non-small Cell Lung Cancer (NSCLC) in 128 participants. Currently enrolling.

Timeline

21 December 2023

Primary endpoint
1 November 2027

1 March 2028

Quick facts

Lead sponsor	Swiss Cancer Institute
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	128
Start date	21 December 2023
Primary completion	1 November 2027
Estimated completion	1 March 2028
Sites	7 locations across Switzerland

Drugs / interventions tested

• Systemic therapy alone or in combination with LAT (surgery and/or radiotherapy)
• Surgery
• Radiotherapy — full drug profile →

Conditions studied

• Non-small Cell Lung Cancer (NSCLC) — all drugs for Non-small Cell Lung Cancer (NSCLC) →
• Stage IV — all drugs for Stage IV →

Sponsor

Swiss Cancer Institute

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer (NSCLC) or Stage IV. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Unfortunately, most patients are already at a very advanced stage when they are diagnosed with lung cancer, i.e. the cancer has already spread outside the lungs forming metastases. The current standard of care therapy at this advanced stage of lung cancer includes systemic anti-cancer therapy such as chemotherapy, immunotherapy to boost the body's immune response, or targeted therapy that directly hinders tumor growth. In this study, the aim is to find out whether it is better if, after a good response to the standard therapy, the remains of main tumor and the metastases are additionally treated by surgery and/or radiation.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

1. Complex situations in lung cancer: multifocal disease, oligoprogression and oligorecurrence.
   Werner R, Steinmann N, Decaluwe H, Date H, et al · · 2024 · cited 5× · PMID 38811031 · DOI 10.1183/16000617.0200-2023
2. Integrated management of immunotherapy and radiotherapy for patients with metastatic non-small cell lung cancer: a narrative review of current landscape and future directions.
   Liang X, Li F, Zhang Y, Hu P, et al · · 2026 · PMID 41982689 · DOI 10.21037/tlcr-2026-1-0018